Boston Family Office LLC Sells 6,365 Shares of Zoetis Inc. (NYSE:ZTS)

Boston Family Office LLC lowered its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 18.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,528 shares of the company's stock after selling 6,365 shares during the quarter. Boston Family Office LLC's holdings in Zoetis were worth $4,485,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Geode Capital Management LLC grew its holdings in shares of Zoetis by 1.8% during the 4th quarter. Geode Capital Management LLC now owns 10,617,897 shares of the company's stock valued at $1,726,075,000 after purchasing an additional 190,137 shares during the last quarter. HighPoint Advisor Group LLC boosted its position in Zoetis by 106.7% during the fourth quarter. HighPoint Advisor Group LLC now owns 25,001 shares of the company's stock valued at $4,073,000 after buying an additional 12,908 shares during the period. Franklin Resources Inc. grew its stake in shares of Zoetis by 6.5% during the fourth quarter. Franklin Resources Inc. now owns 250,152 shares of the company's stock valued at $40,757,000 after buying an additional 15,298 shares during the last quarter. Edmond DE Rothschild Holding S.A. increased its holdings in shares of Zoetis by 82.3% in the fourth quarter. Edmond DE Rothschild Holding S.A. now owns 267,482 shares of the company's stock worth $43,581,000 after buying an additional 120,732 shares during the period. Finally, Axiom Investors LLC DE lifted its stake in shares of Zoetis by 11.9% in the 4th quarter. Axiom Investors LLC DE now owns 490,707 shares of the company's stock valued at $79,951,000 after acquiring an additional 52,125 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors.

Remove Ads

Analysts Set New Price Targets

Several research firms recently issued reports on ZTS. Piper Sandler raised their price target on Zoetis from $200.00 to $205.00 and gave the stock an "overweight" rating in a research report on Thursday, February 27th. UBS Group assumed coverage on shares of Zoetis in a report on Monday, December 9th. They issued a "neutral" rating and a $196.00 target price on the stock. StockNews.com upgraded shares of Zoetis from a "hold" rating to a "buy" rating in a report on Friday, March 7th. Barclays upped their price objective on shares of Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research note on Friday, February 14th. Finally, Morgan Stanley cut their target price on Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a research note on Friday, February 14th. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $215.90.

Zoetis Price Performance

NYSE:ZTS traded down $4.16 on Thursday, reaching $159.34. 3,275,464 shares of the company's stock traded hands, compared to its average volume of 2,601,810. The stock has a 50-day simple moving average of $166.20 and a 200-day simple moving average of $173.98. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $200.33. The firm has a market cap of $71.35 billion, a PE ratio of 29.13, a P/E/G ratio of 2.78 and a beta of 0.94. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping the consensus estimate of $1.37 by $0.03. The business had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. Equities research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be issued a $0.50 dividend. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.26%. Zoetis's dividend payout ratio (DPR) is 36.56%.

Insider Buying and Selling

In other news, EVP Roxanne Lagano sold 326 shares of the company's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $170.00, for a total transaction of $55,420.00. Following the sale, the executive vice president now directly owns 15,781 shares in the company, valued at approximately $2,682,770. This represents a 2.02 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Willie M. Reed sold 1,210 shares of the business's stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the sale, the director now directly owns 11,245 shares in the company, valued at $1,868,244.30. The trade was a 9.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,862 shares of company stock worth $312,254. Corporate insiders own 0.16% of the company's stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.